GENFIT acquires rights to novel asset
LILLE, FRANCE: GENFIT (Nasdaq: GNFT), a late-stage biopharmaceutical company, announced acquisition of exclusive rights from Genoscience Pharma to develop and commercialize the investigational treatment GNS561 in cholangiocarcinoma in the United States, Canada and Europe, including the United Kingdom and Switzerland….